You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
RuBi GABA trimethylphosphine
Biological Activity for RuBi GABA trimethylphosphine
RuBi GABA trimethylphosphine is a modified version of RuBi-GABA (Cat. No. 3400). Suppresses cortical local field potential (LFP) activity in anesthetized mice after activation with a blue laser pulse (473 nm); inhibits neural activity.
Sold under licence from Columbia University
Technical Data for RuBi GABA trimethylphosphine
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for RuBi GABA trimethylphosphine
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for RuBi GABA trimethylphosphine
The following data is based on the product molecular weight 904.56. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||2.21 mL||11.06 mL||22.11 mL|
|2.5 mM||0.44 mL||2.21 mL||4.42 mL|
|5 mM||0.22 mL||1.11 mL||2.21 mL|
|25 mM||0.04 mL||0.22 mL||0.44 mL|
Product Datasheets for RuBi GABA trimethylphosphine
References for RuBi GABA trimethylphosphine
References are publications that support the biological activity of the product.
Lopes-dos-Santos et al (2011) In vivo photorelease of GABA in the mouse cortex. Braz.J.Med.Biol.Res. 44 688 PMID: 21755263
Filevich et al (2013) RuBiGABA-2: a hydrophilic caged GABA with long wavelength sensitivity. Photochem.Photobiol.Sci. 12 1565 PMID: 23674097
If you know of a relevant reference for RuBi GABA trimethylphosphine, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: RuBi GABA trimethylphosphine, RuBi GABA trimethylphosphine supplier, RuBi, GABA, caged, agonists, RUBIGABA2, RUBIGABA-2, RuBi-GABA-PMe3, GABAB, Receptors, GABAA, GABAA-rho, Miscellaneous, Caged, Compounds, 4709, Tocris Bioscience
Citations for RuBi GABA trimethylphosphine
Citations are publications that use Tocris products.
Currently there are no citations for RuBi GABA trimethylphosphine. Do you know of a great paper that uses RuBi GABA trimethylphosphine from Tocris? Please let us know.
Reviews for RuBi GABA trimethylphosphine
There are currently no reviews for this product. Be the first to review RuBi GABA trimethylphosphine and earn rewards!
Have you used RuBi GABA trimethylphosphine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GABA Receptors Scientific Review
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.